8-K: AN2 Therapeutics Pauses Phase 3 Enrollment for Epetraborole Trial Due to Efficacy Concerns

AN2 Therapeutics has voluntarily paused enrollment in its Phase 3 clinical trial for epetraborole due to potentially lower than expected efficacy observed in a blinded analysis of the Phase 2 study.

Summary

• AN2 Therapeutics has decided to temporarily halt enrollment in the Phase 3 portion of its EBO-301 clinical trial, which is evaluating epetraborole for treatment-refractory Mycobacterium avium complex (MAC) lung disease.
• This decision was made after a blinded analysis of the ongoing Phase 2 study indicated potentially lower than expected efficacy.
• The pause is not due to any safety concerns.
• The Phase 2 part of the trial, which completed enrollment in September 2023 with 80 patients, is intended to inform the Phase 3 part of the trial.
• The Phase 3 part of the trial has enrolled nearly 100 patients, which is faster than initially anticipated.
• The company expects to announce topline data from the Phase 2 part of the trial in summer 2024.
• The pause will allow for further evaluation of study data and for the Data Safety Monitoring Board (DSMB) to conduct an unblinded assessment and recommend next steps, which could include changes to the Phase 3 study protocol.
• Patients already enrolled in the trial will continue to receive treatment.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the pause in Phase 3 enrollment and concerns about efficacy, although the company is taking a proactive approach to address the issues. The lack of safety concerns is a positive, but the overall outlook is uncertain.

Positives

• The pause in enrollment is not due to safety concerns.
• The Phase 3 enrollment rate was faster than initially anticipated.
• Patients already enrolled in the trial will continue to receive treatment.
• The company is taking a proactive approach to evaluate the data and make necessary adjustments to the trial.

Negatives

• The voluntary pause in Phase 3 enrollment is due to potentially lower than expected efficacy.
• The need to pause the trial may indicate a potential setback in the development of epetraborole.
• The trial may require protocol modifications or redesign.

Risks

• The DSMB's recommendations could lead to significant changes in the Phase 3 study protocol.
• There is a risk that the company may not be able to resume enrollment in the Phase 3 trial.
• The trial may be terminated if the efficacy is not sufficient.
• The company's ability to obtain regulatory approvals for epetraborole is uncertain.
• The company may need additional capital to achieve its goals.

Future Outlook

The company will further evaluate study data and the DSMB will conduct an unblinded assessment to determine next steps, which could include changes to the Phase 3 study protocol. The company anticipates announcing topline data from the Phase 2 part of the trial in summer 2024.

Management Comments

• The company has decided to voluntarily pause Phase 3 enrollment pending further data review.
• The decision was not due to safety concerns.

Industry Context

The development of new treatments for MAC lung disease is an area of unmet medical need, and this pause in enrollment highlights the challenges in developing effective therapies for this condition. Other companies are also working on treatments for MAC, and the outcome of AN2's trial will be closely watched by the industry.

Comparison to Industry Standards

• The trial design, using a double-blind, placebo-controlled approach, is consistent with industry standards for evaluating new drug candidates.
• The adaptive design of the trial allows for adjustments based on the Phase 2 results, which is a common practice in clinical trials.
• The enrollment rate in Phase 3 was faster than anticipated, which is a positive sign, but the pause due to efficacy concerns is a setback.
• Other companies such as Insmed with Arikayce have faced challenges in developing treatments for MAC, highlighting the complexity of this disease.

Stakeholder Impact

• Shareholders may be concerned about the potential delay and uncertainty surrounding the development of epetraborole.
• Patients with MAC lung disease may face a delay in the availability of a new treatment option.
• Employees of AN2 Therapeutics may experience uncertainty about the future of the program.

Next Steps

• The company will further evaluate study data.
• The DSMB will conduct an unblinded assessment.
• The company will determine next steps, which could include changes to the Phase 3 study protocol.
• The company expects to announce topline data from the Phase 2 part of the trial in summer 2024.

Key Dates

Keywords

epetraborole, clinical trial, Phase 3, Phase 2, Mycobacterium avium complex, MAC lung disease, Data Safety Monitoring Board, DSMB, efficacy, enrollment, treatment-refractory